secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001549595-25-000115
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix initiates pivotal Phase 2 DAYBreak trial of bexobrutideg in r/r CLL with 600 mg QD dose
--------------------------------------------------------------------------------

- DAYBreak Phase 2 will enroll ~100 r/r CLL/SLL patients after prior cBTKi, ncBTKi, and BCL-2i; primary endpoint is ORR by IRC.
- 600 mg QD dose selected via Phase 1b randomized cohort; aligned with FDA, MHRA, and EMA for accelerated approval pathway.
- Confirmatory Phase 3 trial planned for H1 2026 with ~400 patients comparing bexobrutideg to pirtobrutinib or chemoimmunotherapy.
- NX-1607 Phase 1a data showed disease control rate 49.3% in 82 patients; confirmed partial response in MSS colorectal cancer.
- Preclinical data presented claim superior degradation potency and selectivity across BTK mutations; investor webcast held Oct 22.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000115/0001549595-25-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000115/nrix-20251022.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer